Erratum To: Pharmacokinetics in Patients With Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus

Clinical Pharmacokinetics - United Kingdom
doi 10.1007/s40262-014-0205-7
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Comparison of Efficacy Between Incretin-Based Therapies for Type 2 Diabetes Mellitus

BMC Medicine
Medicine
2012English

Incorporating Incretin-Based Therapies Into Clinical Practice for Patients With Type 2 Diabetes

Advances in Therapy
MedicinePharmacology
2014English

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

Advances in Therapy
MedicinePharmacology
2015English

Management of Type 2 Diabetes Mellitus in Chronic Kidney Disease

Current Medical Research and Opinion
Medicine
2014English

Effect of Long-Term Incretin-Based Therapies on Ischemic Heart Diseases in Patients With Type 2 Diabetes Mellitus: A Network Meta-Analysis

Scientific Reports
Multidisciplinary
2017English

Role of Incretin‐based Therapy in Hospitalized Patients With Type 2 Diabetes

Journal of Diabetes Investigation
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2019English

Cardiovascular Effects of Incretin-Based Therapies in Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

The Lancet Diabetes and Endocrinology
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Cystatin C Study in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Medical News of North Caucasus
Medicine
2016English

Correction: Cardiovascular Effect of Incretin-Based Therapy in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis

PLoS ONE
Multidisciplinary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy